Lindsey Roeker, MD

Lindsey Roeker, MD, discusses the rationale for combining venetoclax with BTK inhibitors for use in patients with chronic lymphocytic leukemia.

Lindsey Roeker, MD, discusses the emerging role of minimal residual disease as a predictive end point in chronic lymphocytic leukemia.